CBS Fires Veteran Correspondent Scott Pelley Amid ’60 Minutes’ Editorial Turmoil
Veteran '60 Minutes' correspondent Scott Pelley has been fired by CBS News amidst significant internal turmoil.
Investor topic hub
Economy
Macro stories that shape growth, inflation, labor markets, household spending, public budgets, and investor expectations.
Inflation and rate path
Growth and labor-market momentum
Consumer demand and credit pressure
Sellers Delist Homes at Fastest Rate Since 2020 Amid Higher Mortgage Rates
Frustrated home sellers nationwide delisted properties in April at a pace not seen since March 2020, driven by higher mortgage rates and weaker consumer...
Morgan Stanley to Open Wealth Management Funnel to External AI Agents
Morgan Stanley will soon allow external AI agents to directly access its stock administration platforms, ShareWorks and Equity Edge.
Private Sector Adds 122,000 Jobs in May, Exceeding Expectations, ADP Reports
The private sector added 122,000 jobs in May, exceeding expectations.
Macy’s Reports Strongest Q1 Growth in Four Years, Raises Full-Year Guidance
Macy's posted its strongest fiscal first-quarter comparable sales growth in four years, leading the retailer to raise its full-year guidance.
Audemars Piguet Watch Prices Stable Despite Swatch Collaboration Concerns
Audemars Piguet's collaboration with Swatch, the Royal Pop collection, sparked fears of brand dilution.
President Donald Trump Accelerates Psychedelic Research for Mental Health Treatment
President Donald Trump signed an executive order to accelerate research into psychedelic drugs for mental illness.
Barry Diller’s People Inc. Offers to Acquire Casino Giant MGM Resorts for $48.30 Per Share
Barry Diller's People Inc. has made an offer to purchase casino giant MGM Resorts for $48.30 per share.
UAW Strike at Dauch Corp. Threatens General Motors Truck Production
Nearly 1,000 UAW workers at Dauch Corp. in Michigan are on strike, impacting General Motors' pickup truck production.
Akeso and Summit Therapeutics’ Ivonescimab Shows Improved Survival in China Lung Cancer Trial, Fueling Market Debate
Akeso and Summit Therapeutics' experimental lung cancer drug, ivonescimab, demonstrated a 34% reduction in death risk in a late-stage China trial, offering extended survival...